Patents Assigned to LSIP, LLC
  • Patent number: 8759323
    Abstract: Provided is a novel protein phosphatase inhibitor. The protein phosphatase inhibitor contains, as an active ingredient, a silicon compound represented by the following general formula (1) or a salt thereof, wherein R1, R2 and R3 are the same or different and represent a hydrocarbon group having 1 to 12 carbon atoms; X represents an optionally substituted hydrocarbon group having 3 to 36 carbon atoms or an optionally substituted heterocyclic group; and n represents an integer of 0 or 1.
    Type: Grant
    Filed: October 2, 2009
    Date of Patent: June 24, 2014
    Assignee: LSIP, LLC
    Inventors: Kazuyasu Sakaguchi, Keiji Tanino, Yoshiro Chuman, Fumihiko Yoshimura, Hiroaki Yagi
  • Publication number: 20140137274
    Abstract: PROBLEM There are provided induced malignant stem cells capable of in vitro proliferation that are useful in cancer research and drug discovery for cancer therapy, as well as processes for production thereof, cancer cells derived from these cells, and applications of these cells.
    Type: Application
    Filed: November 30, 2012
    Publication date: May 15, 2014
    Applicants: LSIP, LLC, National Cancer Center
    Inventors: National Cancer Center, LSIP, LLC
  • Patent number: 8686127
    Abstract: This invention relates to an agent, a composition and a product comprising at least one apoptosis-inducing substance, and at least one substance which inhibits expression and/or activity of an apoptosis-inhibiting substance; a method for inducing apoptosis or for treating a proliferative disease using one or more of them; a nucleic acid construct comprising a nucleic acid molecule encoding a protein to be expressed and a nucleic acid molecule which inhibits expression of an undesired protein; and a method for expressing a desired protein in a cell while inhibiting the expression of an undesired protein.
    Type: Grant
    Filed: April 13, 2009
    Date of Patent: April 1, 2014
    Assignee: LSIP, LLC
    Inventors: Masashi Idogawa, Yasushi Sasaki, Takashi Tokino
  • Publication number: 20130203062
    Abstract: The present invention provides a method for detecting rhabdomyosarcoma comprising evaluating expression of at least one kind of miRNA selected from the group consisting of hsa-miR-1, hsa-miR-133a, hsa-miR-133b, and hsa-miR-206 in a sample. derived from body fluid.
    Type: Application
    Filed: April 7, 2011
    Publication date: August 8, 2013
    Applicants: LSIP, LLC, KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION
    Inventors: Hajime Hosoi, Mitsuru Miyachi
  • Publication number: 20110288050
    Abstract: Provided is a novel protein phosphatase inhibitor. The protein phosphatase inhibitor contains, as an active ingredient, a silicon compound represented by the following general formula (1) or a salt thereof, wherein R1, R2 and R3 are the same or different and represent a hydrocarbon group having 1 to 12 carbon atoms; X represents an optionally substituted hydrocarbon group having 3 to 36 carbon atoms or an optionally substituted heterocyclic group; and n represents an integer of 0 or 1.
    Type: Application
    Filed: October 2, 2009
    Publication date: November 24, 2011
    Applicant: LSIP, LLC
    Inventors: Kazuyasu Sakaguchi, Keiji Tanino, Yoshiro Chuman, Fumihiko Yoshimura, Hiroaki Yagi